Is Insmed Incorporated (INSM) a Buy, Sell, or Hold?
Insmed Incorporated
NASDAQ:INSM
$109.1841 USD
-$0.93 (-0.84%)
- Volume
- 973.24K
- Average Volume
- 3.77M
- Market Capitalization
- $23.67B
- P/E Ratio
- -18.99
- Dividend Yield
- 0.00%
- Price Target
- $205.00
- Year High
- $212.75
- Year Low
- $90.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.47
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | William H. Lewis |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | INSM |
| CUSIP | 457669307 |
| CIK | 0001104506 |
| Web | https://www.insmed.com |
| Phone | 908 977 9900 |
| Currency | USD |
| Employees | 1664 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.06 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.47 |
| Quick Ratio | 4.10 |
| Cash Ratio | 1.61 |
Sales & Book Value
| Annual Sales | $606.42M |
| Price / Sales | 28.88 |
| Cash Flow | -4.42 |
| Price / Cash Flow | -24.87 |
| Price / Book | 33.38 |
Price Target and Rating
| Average Stock Price Forecast | $205.00 |
| High Stock Price Forecast | $245.00 |
| Low Stock Price Forecast | $161.00 |
| Forecast Upside/Downside | -46.74% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 35 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.41 |
| Trailing P/E Ratio | -18.99 |
| PEG Ratio | -13.92 |
| P/E Growth | -13.92 |
| Net Income | $-1.28B |
| Net Margin | -144.44% |
| Pretax Margin | -143.76% |
| Return on Equity | -130.11% |
| Return on Assets | -57.02% |
Financials Score
| AltmanZ Score | 5.80 |
| Piotroski Score | 4.00 |
| Working Capital | 1.25B |
| Total Assets | 2.08B |
| Ebit | -1.1B |
| Market Cap | 23.64B |
| Total Liabilities | 1.37B |
Poll Results
About Insmed Incorporated (NASDAQ:INSM) Stock
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arte ... rial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review
2026-07-14 08:53:00
Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.
2026-06-25 05:05:00
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis —Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
2026-06-23 07:00:00
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today.
The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms
2026-06-22 14:19:15
The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).
Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy
2026-06-22 07:30:38
Insmed is maintained at "Strong Buy" due to robust pipeline progress and expanding commercial execution. INSM's key catalysts include ARIKAYCE's sNDA submission for 1st-line MAC Lung Disease in H2 2026 and ongoing regulatory expansion efforts in Japan. TPIP advances with phase 3 PALM-PAH and PALM-ILD studies, targeting large PAH and PH-ILD markets with potential best-in-class, once-daily dosing.
Nasdaq-100 Index® June 2026 Quarterly Changes
2026-06-11 20:00:00
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index (NDX), which will become effective prior to market open on Monday, June 22, 2026. The following five companies will be added to the Index: Astera Labs, Inc.
2026-06-09 13:22:09
Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-06-04 07:00:00
BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees.
Frequently Asked Questions
-
What is the current Insmed Incorporated (INSM) stock price?
-
Insmed Incorporated(NASDAQ:INSM) stock price is $109.1841 in the last trading session. During the trading session, INSM stock reached the peak price of $212.75 while $90.39 was the lowest point it dropped to. The percentage change in INSM stock occurred in the recent session was --0.84% while the dollar amount for the price change in INSM stock was -$-0.93.
-
INSM's industry and sector of operation?
-
The NASDAQ listed INSM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INSM?
-
Christie Camelio | Chief Compliance Officer
Claire Mulhearn | Vice President of Corporate Communications
Sara Bonstein | Chief Financial Officer
Bryan Dunn | Vice President of Investor Relations
Martina Flammer | Chief Medical Officer -
How many employees does INSM have?
-
Number of INSM employees currently stands at 1664. INSM operates from 700 US Highway 202/206, Bridgewater, NJ 08807, US.
-
Link for INSM official website?
-
Official Website of INSM is: https://www.insmed.com
-
How do I contact INSM?
-
INSM could be contacted at phone #908 977 9900 and can also be accessed through its website. INSM operates from 700 US Highway 202/206, Bridgewater, NJ 08807, US.
-
How many shares of INSM are traded daily?
-
The average number of INSM shares traded daily for last 3 months was 3.77M.
-
What is the market cap of INSM currently?
-
The market value of INSM currently stands at $23.67B with its latest stock price at $109.1841